Windlas Biotech Ltd

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Windlas Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite a recent downgrade in its overall Mojo Grade to Sell. This recalibration in price-to-earnings and price-to-book value metrics, when analysed against historical trends and peer benchmarks, suggests a nuanced investment opportunity within the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Windlas Biotech Ltd has seen a notable shift in its valuation parameters, moving from fair to attractive territory despite ongoing sector headwinds. With a current price of ₹791.95 and a market cap categorised as small-cap, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Ltd., a contract development and manufacturing organisation (CDMO) in the pharmaceutical sector, reported a mixed performance for the quarter ended March 2026, with net profit declining 1.78% year-on-year to ₹15.99 crores despite revenue growth of 17.66%. The ₹1,603-crore market capitalisation company has witnessed significant margin compression, raising concerns about operational efficiency amidst an otherwise healthy top-line expansion.

Windlas Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade from Hold to Sell by MarketsMOJO on 4 February 2026, the stock’s technical parameters reveal a cautiously evolving landscape that investors should carefully analyse.

Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 15 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Windlas Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, signalling increased bearishness. The stock’s recent price action and technical indicators suggest a deteriorating trend, with the MarketsMOJO Mojo Grade downgraded from Hold to Sell as of 4 February 2026, reflecting growing investor caution amid weakening momentum.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

The Sensex advanced 1.79% on 15 Apr 2026, yet Windlas Biotech Ltd outpaced the broader market with a 7.09% gain, touching an intraday high of Rs 875.45. This 5.15-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market tailwind.

Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 12 April 2026, providing investors with the latest insights into its performance and outlook.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Windlas Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from Hold to Sell by MarketsMOJO on 4 February 2026, the stock’s price action and technical indicators suggest a cautiously evolving outlook for investors.

Windlas Biotech Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating, reflecting evolving market perceptions amid a challenging sector backdrop. Despite a modest day gain of 1.90%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest a more tempered price attractiveness compared to its historical averages and peer group benchmarks.